Article Text

Download PDFPDF
Removal of a migrated dexamethasone implant (Ozurdex) from the anterior chamber using an intravenous cannula
  1. Jae Yee Ku1,2,
  2. Karl Mercieca2,3 and
  3. Kenneth Yau2
  1. 1Department of Eye and Vision Science, University of Liverpool, Liverpool, UK
  2. 2Department of Glaucoma, Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK
  3. 3Department of Ophthalmology, Universitäts-Augenklinik Bonn, Bonn, Germany
  1. Correspondence to Dr Jae Yee Ku; jku{at}


Ozurdex is a dexamethasone intravitreal implant used for the treatment of macular oedema. A rare but serious complication is the migration of the implant into the anterior chamber (AC) in eyes with absent or incomplete posterior capsules that may lead to corneal decompensation. We report the case of a 75-year-old woman who presented with a 1-day history of decreased vision in her left eye. She had a history of complicated cataract surgery and had received multiple Ozurdex implants for postoperative cystoid macular oedema in the same eye. She had significant left corneal decompensation and a mobile Ozurdex implant in the AC. We report a simple but novel surgical technique for removing an Ozurdex implant from the AC using an intravenous cannula (Venflon). This technique can also be applied to removing a fluocinolone acetonide (Iluvien) implant in similar situations.

  • eye
  • anterior chamber
  • macula
  • retina
  • surgery

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors JK, KM and KY contributed to the study design and data acquisition, and drafted and revised the work. All authors have read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.